Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
74 studies found for:    "Wegener granulomatosis"
Show Display Options
Rank Status Study
1 Completed Etanercept for Wegener's Granulomatosis
Condition: Wegener's Granulomatosis
Intervention: Drug: Etanercept
2 Terminated Clinical Study Comparing the New Immunosuppressive Drug Gusperimus With the Conventional Treatment in Wegener's Granulomatosis
Condition: Wegeners Granulomatosis
Interventions: Drug: Gusperimus + glucocorticoids;   Drug: cyclophosphamide followed by methotrexate (azathioprine) + glucocorticoids or methotrexate (azathioprine) + glucocorticoids
3 Completed Phase II Study on Gusperimus in Patients With Refractory Wegener's Granulomatosis
Condition: Wegener's Granulomatosis
Intervention: Drug: Gusperimus
4 Completed Daclizumab to Treat Wegener's Granulomatosis
Condition: Wegener's Granulomatosis
Intervention: Drug: Daclizumab
5 Completed
Has Results
Abatacept in Treating Adults With Mild Relapsing Wegener's Granulomatosis
Condition: Wegener's Granulomatosis
Intervention: Drug: Abatacept
6 Completed An Open Label Pilot Study Examining the Use of Rituximab in Patients With Wegener's Granulomatosis Who Have Experienced Disease Relapse on Standard Therapies
Condition: Wegener's Granulomatosis
Intervention: Drug: Rituximab
7 Completed Study of One Protein Implicated in Wegener Disease
Condition: Wegener's Granulomatosis
Intervention: Biological: Physiopathology Endpoint Classification
8 Completed Treatment of Wegener's Granulomatosis With Cyclophosphamide
Conditions: Vasculitis;   Wegener's Granulomatosis
Intervention: Drug: cyclophosphamide
9 Completed Etanercept to Treat Wegener's Granulomatosis
Conditions: Vasculitis;   Wegener's Granulomatosis
Intervention: Drug: Etanercept
10 Completed Mycophenolate Mofetil to Treat Wegener's Granulomatosis and Related Vascular Inflammatory Conditions
Conditions: Vasculitis;   Wegener's Granulomatosis
Intervention: Drug: Mycophenolate Mofetil
11 Completed Phase I Trial of Recombinant Human Interleukin-10 (SCH 52000) in Patients With Wegener's Granulomatosis
Conditions: Vasculitis;   Wegener's Granulomatosis
Intervention: Drug: Interleukin-10
12 Completed Comparison of Treatments to Maintain Disease Remission in Patients With Wegener's Granulomatosis and Related Vasculitis Syndromes
Conditions: Vasculitis;   Wegener's Granulomatosis
Intervention: Drug: Mycophenolate Mofetil
13 Recruiting Neutrophils as Prognostic Factors in Granulomatosis With Polyangiitis (Formerly Named Wegener's Granulomatosis)
Condition: Granulomatosis With Polyangiitis
Interventions: Other: Blood samples and clinical data;   Other: Blood sample
14 Not yet recruiting Rituximab for the Otolaryngologic Manifestations of Granulomatosis With Polyangiitis
Condition: Granulomatosis With Polyangiitis (Wegener's Granulomatosis)
Interventions: Drug: Rituximab;   Other: Placebo
15 Completed Analysis of Bronchial Tissue and Fluid in Patients With Wegener's Granulomatosis
Conditions: Inflammation;   Vasculitis;   Wegener's Granulomatosis
Intervention:
16 Recruiting A Study Evaluating the Safety and Efficacy of Rituximab in Combination With Glucocorticoids in Participants With Wegener's Granulomatosis or Microscopic Polyangitis
Condition: Wegener's Granulomatosis or Microscopic Polyangiitis
Interventions: Drug: Methylprednisolone;   Drug: Prednisone;   Drug: Rituximab
17 Not yet recruiting Rituximab in Eosinophilic Granulomatosis With Polyangiitis
Condition: Eosinophilic Granulomatosis With Polyangiitis (EGPA)
Interventions: Drug: Rituximab;   Drug: Placebo-rituximab;   Drug: Cyclophosphamide;   Drug: Placebo-cyclophosphamide
18 Recruiting A Phase IIa Study of Intravenous Rituximab in Pediatric Participants With Severe Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis
Condition: Granulomatosis With Polyangiitis
Intervention: Drug: Rituximab
19 Completed Cyclophosphamide and Prednisone Followed by Methotrexate To Treat Vasculitides
Conditions: Vasculitis;   Wegener's Granulomatosis
Intervention:
20 Active, not recruiting
Has Results
An Observational Study of The Safety of MabThera/Rituxan (Rituximab) in Patients With Granulomatosis With Polyangiitis (Wegener's) or Microscopic Polyangiitis
Conditions: Granulomatosis With Polyangiitis;   Microscopic Polyangiitis
Intervention: Drug: Rituximab

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.